NYSE
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies and commercial real estate assets. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | $802,000.00 | $410,000.00 | $279,000.00 | $637,000.00 | $917,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.5M | -$28.2M | -$60.5M | -$15.0M | -$102.6M | -$29.2M |
| Net income | -$10.8M | -$23.1M | -$124.7M | -$1.9M | -$34.4M | -$30.5M |
| Diluted EPS | — | -$1.49 | -$6.31 | -$0.08 | -$1.45 | -$1.04 |
| Operating cash flow | -$4.7M | -$15.6M | -$26.1M | -$10.9M | -$7.8M | -$18.9M |
| Free cash flow | -$5.2M | -$15.8M | -$26.1M | — | -$7.9M | -$18.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -172.4% | -3516.1% | -14750.5% | -5391.8% | -16111.0% | -3179.8% |
| Net margin | -219.0% | -2875.4% | -30404.4% | -672.4% | -5401.9% | -3328.2% |
| Line item | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $165,000.00 | $128,000.00 | $77,000.00 | $362,000.00 | $350,000.00 | $240,000.00 | $211,000.00 | $179,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.8M | -$3.8M | -$6.6M | -$5.9M | -$12.8M | -$10.1M | -$6.7M | -$6.9M |
| Net income | -$4.5M | -$9.0M | -$4.6M | -$4.8M | -$290,000.00 | -$9.8M | -$6.4M | -$4.2M |
| Diluted EPS | -$0.19 | -$0.37 | -$0.19 | -$0.19 | -$0.29 | -$0.19 | -$0.13 | -$0.08 |
| Operating cash flow | -$2.9M | -$3.0M | -$2.3M | -$3.2M | -$10.4M | -$6.8M | -$7.5M | -$7.3M |
| Free cash flow | — | -$3.0M | -$2.3M | -$3.2M | -$10.4M | — | — | -$7.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2330.3% | -3003.1% | -8622.1% | -1633.4% | -3646.6% | -4225.4% | -3154.0% | -3838.0% |
| Net margin | -2707.9% | -7035.9% | -6027.3% | -1320.2% | -82.9% | -4090.0% | -3041.2% | -2360.9% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-21 | Polinsky David· Chief Financial Officer | Tax withholding | 2,386 | $2.64 | $6,287.11 | filing |
| 2026-06-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Award | 142,857 | $1.75 | $249,999.75 | filing |
| 2026-06-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Tax withholding | 8,786 | $2.33 | $20,471.38 | filing |
| 2026-03-21 | Polinsky David· Chief Financial Officer | Tax withholding | 2,318 | $1.28 | $2,955.45 | filing |
| 2026-03-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Tax withholding | 9,826 | $1.50 | $14,763.57 | filing |
| 2026-01-28 | WEISS MICHAEL J | Award | 39,370 | $1.27 | $49,999.90 | filing |
| 2026-01-28 | STEIN MARK N | Award | 39,370 | $1.27 | $49,999.90 | filing |
| 2026-01-28 | Sieger Markus | Award | 29,528 | $1.27 | $37,500.56 | filing |
| 2026-01-28 | GRAYSON ALAN | Award | 6,562 | $1.27 | $8,333.74 | filing |
| 2026-01-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Award | 75,000 | $1.25 | $93,637.50 | filing |
| 2026-01-13 | Polinsky David· Chief Financial Officer | Award | 50,000 | $1.25 | $62,425.00 | filing |
| 2026-01-13 | Polinsky David· Chief Financial Officer | Tax withholding | 4,865 | $1.25 | $6,073.95 | filing |
| 2025-12-21 | Polinsky David· Chief Financial Officer | Tax withholding | 1,961 | $1.29 | $2,519.89 | filing |
| 2025-12-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Tax withholding | 9,867 | $1.50 | $14,775.83 | filing |
| 2025-10-25 | Polinsky David· Chief Financial Officer | Tax withholding | 4,180 | $1.35 | $5,643.00 | filing |
| 2025-09-23 | Polinsky David· Chief Financial Officer | Tax withholding | 1,284 | $1.48 | $1,900.32 | filing |
| 2025-09-21 | Polinsky David· Chief Financial Officer | Tax withholding | 1,970 | $1.49 | $2,935.30 | filing |
| 2025-09-13 | JONAS HOWARD S· Exec Chairman, CEO & President | Tax withholding | 9,905 | $1.35 | $13,322.23 | filing |
| 2025-06-21 | Polinsky David· Chief Financial Officer | Tax withholding | 2,347 | $1.60 | $3,743.47 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.